Skip to content

This site is intended for healthcare professionals in the UK only. Prescribing information and adverse event reporting can be found in the footer.

  • Why Nevolat
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • The ideal Nevolat patient
  • How to Administer
    • Dose Titration
    • Method of administration
    • Storage and shelf life
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs
  • Why Nevolat
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • The ideal Nevolat patient
  • How to Administer
    • Dose Titration
    • Method of administration
    • Storage and shelf life
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs

00000000000 | December 2024

Prescribing information can be found here.

  • Navigation
    • Terms of Use
    • HCP Privacy
    • Cookies Policy
    • GDPR

MORE ABOUT US

linkedin

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Zentiva via email to UKMedInfo@zentiva.com
or via phone on 0800 090 2408.

Copyright Zentiva Group, a.s. © 2026

I confirm I am a UK Healthcare Professional (HCP)

This page is dedicated to UK HCPs only. If you are not a UK HCP, you will be directed to the gateway page after clicking on No.

No, I am not Yes, I am